This study evaluated the efficacy and safety of Avastin (bevacizumab, 5 mg/kg intravenously every 2 weeks) in patients with multiple myeloma, relapsed/refractory after at least 2 lines of prior therapy.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
10
Bevacizumab was provided as a concentrate in vials.
Unnamed facility
Salzburg, Austria
Unnamed facility
Vienna, Austria
Unnamed facility
Vienna, Austria
Unnamed facility
Vienna, Austria
Percentage of Participants With a Complete Response or a Partial Response
A complete response was defined as the disappearance of the original monoclonal protein from the blood and urine on at least 2 determinations 6 weeks apart; \< 5% plasma cells in the bone marrow on at least 2 determinations 6 weeks apart; if a skeletal survey is available, no increase in the size or number of lytic bone lesions; and the disappearance of soft tissue plasmacytomas for at least 6 weeks. A partial response was defined as a ≥ 50% reduction of monoclonal protein in the blood on at least 2 determinations 6 weeks apart; if present, reduction in 24-hour urinary light chain excretion by either ≥ 90% or to \< 200 mg for at least 2 determinations 6 weeks apart; ≥ 50% reduction in the size of tissue plasmacytomas for at least 6 weeks; and if a skeletal survey is available, no increase in the size or number of lytic bone lesions.
Time frame: Baseline to the end of the study (up to 1 year)
Progression-free Survival
Progression-free survival was defined as the time from the first dose of study drug to disease progression or death due to progression.
Time frame: Baseline to the end of the study (up to 1 year)
Overall Survival
Overall survival was defined as the time from the first dose of study medication until death.
Time frame: Baseline to the end of the study (up to 1 year)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.